is an agonist of the peroxisome proliferator-activated receptors (PPAR) alpha (α), delta (δ), and gamma (γ), intracellular receptors with major effects on bile acid synthesis and transport as well as lipid metabolism and glucose homeostasis (1):
studies of other PPAR agonists such as pioglitazone and fenofibrate have suggested at least partial improvement in disease activity with their use in several liver diseases
the PPARα agonist bezafibrate has been shown to improve liver tests and histology in patients with primary biliary cholangitis
elafibranor has been shown to improve serum enzymes in several diseases including nonalcoholic steatohepatitis (NASH) and primary biliary cholangitis (1)
NICE states (2):
Elafibranor is recommended, within its marketing authorisation, as an option for treating primary biliary cholangitis in adults, when used:
with ursodeoxycholic acid (UDCA), if the primary biliary cholangitis has not responded well enough to UDCA, or
alone, if UDCA cannot be tolerated
Reference:
LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Elafibranor. [Updated 2024 Jul 24]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK605979/
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.